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The standard use of a single universal broad-range PCR in direct 16S rDNA sequencing from
polybacterial samples leaves the minor constituents at risk of remaining undetected because all
bacterial DNA will be competing for the same reagents. In this article we introduce a set of three
broad-range group-specific 16S rDNA PCRs that together cover the clinically relevant bacteria
and apply them in the investigation of 25 polybacterial clinical samples. Mixed DNA
chromatograms from samples containing more than one species per primer group were analysed
using RipSeq Mixed (iSentio, Norway), a web-based application for the interpretation of
chromatograms containing up to three different species. The group-specific PCRs reduced
complexity in the resulting DNA chromatograms and made the assay more sensitive in situations
with unequal species concentrations. Together this allowed for identification of a significantly
higher number of bacterial species than did standard direct sequencing with a single universal
primer pair and RipSeq analysis (95 vs 51). The method could improve microbiological
diagnostics for important groups of patients and can be established in any laboratory with
experience in direct 16S rDNA sequencing.
INTRODUCTION
Detection and identification of bacteria directly from
clinical samples by broad-range PCR targeting the 16S
rRNA gene followed by DNA sequencing (direct 16S rDNA
sequencing) is a valuable tool in clinical microbiology
(Goldenberger et al., 1997; Harris & Hartley, 2003; Petti
et al., 2008b). RipSeq (iSentio, Bergen, Norway) is a web-
based application for the analysis of mixed DNA
chromatograms that enables the use of this method also
on typical polybacterial specimens such as abscesses and
empyema (Hartmeyer & Justesen, 2010; Kommedal et al.,
2009). However, the use of a single universal first PCR
limits the potential of this approach because the various
bacterial DNAs in a sample will compete for the same
reagents, leaving those present at the lowest concentrations
at risk of remaining undetected. We have found that this
will occur when the difference in concentrations exceeds
1:10, with some variation dependent on primer affinity for
the different targets and the number of 16S rRNA gene
copies in the respective bacteria. Also, the RipSeq
algorithm has been validated for chromatograms contain-
ing up to three different species only (Kommedal et al.,
2008). The aim of this study was to increase the number of
detectable species in polybacterial samples by replacing the
single universal PCR with a set of group-specific broad-
range PCRs.
Based on careful examination of the 16S rRNA gene we
identified a semi-conserved area splitting a wide selection
of human bacterial pathogens into three variant groups:
group A, Gram-positive cocci in chains and non-anaerobic
Gram-positive rods; group B, non-anaerobic Gram-negative
bacteria; group C, Staphylococcus spp. and anaerobic
bacteria not covered in group A. Further research allowed
for the design of three group-specific broad-range primer
pairs (A, B and C) each matching one of the three groups.
All primer pairs amplified approximately the first 500 bp
of the gene. In addition to reducing competition for
Two supplementary tables are available with the online version of this
paper.
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species possible to detect in a sample using RipSeq from
three to three times three. The group-specific primers
were used to reinvestigate 50 clinical samples, of which 25
were known to be polymicrobial and 25 assumed to be
sterile based on previous investigations and the clinical
information available.
METHODS
Primer cross-reactivity. Foreachprimerpair(A,B andC;seeTable1
for primer sequences) cross-reactivity with the other bacterial
groups was investigated by amplifying series of mixes with a falling
ratio of target to non-target DNA (1:1 to 1:1000). In PCRs with
primer pair A and primer pair C cloned 16S rDNA fragments were
used. In reactions with primer pair B genomic DNA was used
instead due to residual Escherichia coli DNA from the cloning
process. Cross-reactivity with human DNA was tested for each
primer pair by amplifying 1000 pg, 100 pg, 10 pg, 1 pg and 0 pg
of target bacterial DNA together with a constant amount of 100 ng
human DNA (Promega).
Cloning and plasmid isolation. The 16S rRNA genes from relevant
bacterial strains were amplified using primers 4F+pH/1542r (Table 1).
The PCR products were cloned into pCR 2.2 TOPO vector and
transformedinto competentE.colicellsusingtheTOPO TAcloning kit
(Invitrogen), following the manufacturer’s protocol. E. coli containing
verified clones were cultured aerobically overnight. Plasmids were
isolated from 2 ml E. coli culture using PureLink Quick Plasmid
Miniprep kit (Invitrogen). The isolated plasmids were diluted to 10
10
ml
21 and frozen at 220 uC until they were used.
Clinical samples. The following polymicrobial specimens were
included together with their corresponding negative controls: brain
abscess (n55), bile (n52), empyema (n56), liver abscess (n53),
ovarian abscess (n51), pancreas abscess (n52), para-aortic abscess
(n51), retro-peritoneal abscess (n52), soft tissue abscess (n52) and
spleen abscess (n51). In addition 25 presumptive negative specimens
and their controls were included: various abscess or abscess-like
specimens (n55), bone biopsy (n51), pericardial fluid (n53),
periprosthetic tissue (n53), peritoneal fluid (n52), pleural fluid
(n56), subdural haematoma (n51) and synovial fluid (n54). All
samples were investigated using the three separate group-specific real-
time PCRs with SYBR-green detection followed by DNA sequencing.
In parallel all samples were analysed using a single universal primer
pair (4F+pD, Table 1) targeting the same part of the 16S rRNA gene
as the group-specific primers (the first 500 bp).
Pre-PCR treatment of clinical samples. The samples had been
extracted using the following protocol. Between 200 and 800 ml
sample material was added to a tube containing a mixture of glass and
ceramic beads (SeptiFast Lysis kit, Roche), together with 400 ml
Bacterial Lysis Buffer (BLB, Roche). Eight hundred microlitres was
the maximum capacity of the bead-tube, and this volume was used
for liquid samples with low viscosity. For other samples 400 ml was
used if available. Two hundred microlitres was the lowest volume that
would still provide 400 ml supernatant for the subsequent DNA
purification and was the lowest volume accepted for all specimens. A
negative control containing lysis buffer and 400 ml PCR-grade water
(Qiagen) was included in every batch of samples. The samples were
run for 2645 s in a FastPrep machine (Cepheid) at speed 6.5. After a
short spin (15800 g, 3 min), 400 ml supernatant was transferred to a
MagNa Pure Compact automated extractor (Roche) and DNA was
extracted and purified using the ‘Total_NA_plasma_100_400’ pro-
gramme according to the manufacturer’s instructions. The resulting
50 ml of eluate was stored at 280 uC until used.
PCR and PCR conditions. PCR primers are listed in Table 1. All
PCRs were performed in 25 ml reaction tubes on a real-time
SmartCycler apparatus (Cepheid) with a final reaction volume of
25 ml. The universal PCR mixture consisted of 12.5 ml ExTaq SYBR
master mix (TaKaRa), 0.4 mM F-primer and 0.4 mM R-primer, 8.5 ml
PCR-grade water and 2 ml template. All group-specific PCR mixtures
consisted of 12.5 ml ExTaq SYBR master mix, 0.8 mM F-primer and
0.4 mM R-primer, 7.5 ml PCR-grade water and 2.0 ml template. The
PCR thermal profile was identical for all reactions and included an
initial polymerase activation step of 10 s at 95 uC followed by 40
cycles of 15 s at 95 uC, 10 s at 64 uC and 20 s at 72 uC.
Negative controls. For all PCRs every sample was run in parallel
with its negative extraction and purification control. For the universal
PCR a sample was defined as positive if the fluorescence threshold
value (Ct) was reached three or more cycles ahead of the negative
control. For the group-specific PCRs the negative control that became
positive first for a given sample defined the cut-off for positivity for
all three group-specific PCRs for that sample (i.e. three or more cycles
before the earliest negative control).
Sequencing. The amplicons from the positive PCRs were collected
by centrifugation from the SmartCycler reaction tubes into a 1.5 ml
Eppendorf tube and cleaned up using the ExoSAP-IT enzymic
degradation kit (Affymetrix). Primers used in the cycle sequencing
reactions are listed in Table 1. Sequencing was performed in a core
facility using the ABI PRISM 1.1 Big-Dye sequencing kit and a 3730
DNA Analyser (Applied Biosystems).
Table 1. Complete list of primers used in this study
Capital letters indicate a locked nucleic acid (LNA). Ambiguous bases:
K5Go rT ,M 5Ao rC ,R 5Ao rG .
Primer Sequence (5§–3§)
Cloning experiment
Forward (4F)* ttg-gag-agt-ttg-atc-mtg-gct-c
Reverse (pH/1542r)D aag-gag-gtg-atc-cag-ccg-ca
Universal PCR
Forward (4F) ttg-gag-agt-ttg-atc-mtg-gct-c
Reverse (pD)D gta-tta-ccg-cgg-ctg-ctg
Universal cycle sequencing
reactions
Forward (Bact-8S-20)d aga-gtt-tga-tcm-tgg-ctc-ag
Reverse (pD) gta-tta-ccg-cgg-ctg-ctg
Group-specific PCRs
Group A-forward -gt-tTg-atc-mtg-gct-cag-rAc
Group B-forward -gt-tTg-atc-mtg-gct-cag-aKtg
Group C-forward agt-ttg-atc-mtg-gct-cag-gAt
Groups A, B, C-reverse (pD) gta-tta-ccg-cgg-ctg-ctg
Group specific cycle
sequencing reactions
Common reverse (534R)* tac-cgc-ggc-tgc-tgg-cac
*Petti et al. (2008a).
DEdwards et al. (1989).
dBosshard et al. (2002).
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were analysed using the RipSeq Mixed web application (http://www.
ripseq.com/login/login.aspx). The RipSeq Mixed algorithm searches
against the ‘16S human pathogen iSentio’ database currently
containing about 1500 reference sequences. The definition of a
positive identification with the RipSeq program has been described
previously (Kommedal et al., 2008). Non-mixed chromatograms were
analysed with both RipSeq and a standard BLAST search against the
GenBank database (http://blast.ncbi.nlm.nih.gov). For the BLAST
searches interpretation criteria given by the Clinical and Laboratory
Standards Institute were followed (Petti et al., 2008a).
RESULTS
Validation of new primers for PCR
The group-specific primers were aligned against 160 high-
quality GenBank reference sequences representing all 129
different genera present in the ‘16S human pathogen
iSentio’ database.
The distribution of genera among the different primer
pairs was as follows: primer pair A, 42 genera [Gram-
positive cocci in chains (including some anaerobic species)
and non-anaerobic Gram-positive rods (including the
aerotolerant genera Actinomyces and Propionibacterium)];
primer pair B, 46 genera (non-anaerobic Gram-negative
bacteria); primer pair C, 41 genera (Staphylococcus spp. and
anaerobic bacteria except those covered for by primer A).
This distribution is to be viewed as a rule of thumb, and
exceptions exist in particular for groups A and C. A more
detailed overview is provided in Supplementary Table S1,
available with the online version of this paper.
The highest tendency for cross-reactivity was between
primer pair A (PCR ‘A’) and bacterial group C and
between primer pair C (PCR ‘C’) and bacterial group A.
For these combinations a 1000-fold higher copy number of
non-target DNA was needed to reach equally high peaks as
the target DNA in the resulting chromatograms. For
primer pair B (PCR ‘B’) co-amplification of group ‘A’ and
‘C’ DNA was not detectable even when present at a 1000-
fold higher concentration than group ‘B’ target DNA
(Supplementary Table S2). No cross-reactivity with human
DNA was observed with any of the primer pairs. In the
solutions with 100 ng human DNA and no added bacterial
DNA, only background bacterial DNA from the reagents
was amplified.
Clinical samples
The polybacterial specimens contained high levels of
bacterial DNA, and with the universal PCR the Ct distance
between a sample and the corresponding negative control
ranged from 220 to 28 cycles. For the specimens positive
by PCR ‘A’ the Ct distance to the negative control ranged
from 217 to 24 cycles. For the specimens negative by PCR
‘A’ the Ct distance ranged from 22.4 to +3.9. The
corresponding intervals for PCR ‘B’ were 216 to 27 and
22.8 to +0.9 and for PCR ‘C’ 217 to 26 and 22.0 to
+4.4. (2 indicates before the negative control and+indi-
cates after.)
Eighty per cent of the samples were affected by antibiotics
administrated prior to specimen collection, and both
standard direct 16S rDNA sequencing and direct sequen-
cing using group-specific primers detected a higher
number of bacteria than did culture. In total 37 species
were found by culture, 51 by standard direct sequencing
and 95 by the group-specific primers. A detailed compar-
ison between these results is given in Table 2. All bacteria
identified with the standard universal primer pair were also
detected with the group-specific primers. For six samples
the two different sequencing protocols yielded identical
results. In the remaining 19 samples a total of 44 additional
bacteria were found by the group-specific primers, ranging
from one to five species per sample. Only 32 out of the 95
bacteria identified by group-specific direct sequencing were
cultivable. Four samples contained one or more isolates
found exclusively by culture. These were a strain of
Staphylococcus haemolyticus isolated from sample 7, scarce
growth of a coagulase-negative Staphylococcus together
with a diphtheroid in sample 23 and two colonies of
Streptococcus parasanguinis in sample 24. In addition an
isolate of Klebsiella sp. from sample 6 was not possible to
read from chromatogram 6B. Some of these isolates might
represent sample contamination, but others are probably
true findings that have not been detected by sequencing
either because they had to compete for reagents with a
more dominant species belonging to the same primer
group or because direct sequencing can have lower
sensitivity than culture in samples with living bacteria.
The detailed results from the group-specific PCRs for the
polybacterial specimens are given in Table 3. Four cases of
cross-reactivity between primer groups were observed. In
sample 7, a group A species was detected as low secondary
peaks in chromatogram 7C. In both samples 11 and 12 a
species belonging to group C was also detectable as the
lower peaks in the A chromatograms. In sample 16,
Enterococcus faecium and Finegoldia magna were amplified
by both PCR ‘A’ and ‘C’, but PCR ‘A’ became positive 8.6
cycles prior to PCR ‘C’. Three of the group-specific
chromatograms were found to be too complex to be
completely resolved, indicating that these samples still
might contain one or more unidentifiable species.
Among the 25 clinical specimens assumed to be negative
(Table 4) one sample (ID 35) was found to be positive by
the universal PCR. It reached Ct at cycle 31.5, exactly three
cycles before the negative control. Melt-point analysis
showed no distinct peak and it was negative by the group-
specific PCRs. Sequencing was unsuccessful and the PCR
result was defined as a false positive. Another sample (ID
50) was positive by PCR ‘B’. This reached Ct at cycle 30.6,
3.1 cycles before the closest negative control. Melt-point
analysis gave an irregular peak. Sequencing produced a
complex chromatogram dominated by a Pseudomonas sp.
and an Acidovorax sp. This corresponds to what we
Direct 16S rDNA sequencing with group-specific primers
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the group-specific primer pairs
ID Sample type Culture* Universal primer Group-specific primers AntibioticD
1 Abscess brain Fusobacterium nucleatum CX, RI
Gemella haemolysans/morbillorum
Parvimonas sp.d Parvimonas sp.
Streptococcus constellatus Streptococcus intermedius S. intermedius
2 Abscess brain F. nucleatum CX, RI
S. constellatus S. intermedius S. intermedius
3 Abscess brain Aggregatibacter aphrophilus CX, MZ
Eikenella sp.
F. nucleatumd F. nucleatum
F. nucleatum subsp. polymorphum
Neisseria elongata
Peptostreptococcus sp. Parvimonas micra P. micra
Streptococcus milleri group S. intermedius S. intermedius
4 Abscess brain No growth Actinomyces meyeri CT, MZ
Campylobacter gracilis
F. nucleatumd F. nucleatum
Prevotella pleuritidis
S. intermedius S. intermedius
5 Abscess brain A. meyeri A. meyeri –
C. gracilis C. gracilis
Eikenella sp.
F. nucleatum Fusobacterium sp. Fusobacterium sp.
Peptostreptococcus sp. Peptostreptococcus sp.
6 Abscess liver E. coli E. coli/Shigella spp. E. coli/Shigella spp. AM
Enterococcus faecium E. faecium/durans E. faecium/durans
Klebsiella sp.
Lactobacillus rhamnosus
Staphylococcus haemolyticus S. haemolyticus
7 Abscess liver G. haemolysans PT
Prevotella melaninogenica P. melaninogenica
Streptococcus mitis group S. mitis group
Streptococcus parasanguinis
S. haemolyticus
8 Abscess liver§ No growth Clostridium perfringens C. perfringens CT
E. coli/Shigella spp. E. coli/Shigella spp.
9 Abscess muscle Eikenella corrodens –
F. nucleatumd F. nucleatum
P. micra
Porphyromonas circumdentaria
Porphyromonas endodontalis P. endodontalis
Streptococcus milleri group S. constellatus/intermedius
10 Abscess ovarian§ F. nucleatum F. nucleatum F. nucleatum –
Peptostreptococcus sp. Parvimonas sp. Parvimonas sp.
11 Abscess pancreas Bacteroides fragilis B. fragilis B. fragilis IP
E. faecium E. faecium
12 Abscess pancreas A. meyeri IP
Campylobacter concisus
P. melaninogenica P. melaninogenica/histicola
Prevotella histicola
CNS Staphylococcus epidermidis S. epidermidis
Ø. Kommedal and others
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ID Sample type Culture* Universal primer Group-specific primers AntibioticD
13 Abscess para-aortic Corynebacterium appendicis –
Diphtheroid Corynebacterium
tuberculostearicum
C. tuberculostearicum
CNS S. haemolyticus S. haemolyticus
14 Abscess psoas No growth Enterobacter hormaechei E. hormaechei MP
E. faecium
15 Abscess spleen Enterococcus sp.
Enterococcus casseliflavus/
gallinarumd
E. casseliflavus/gallinarum Unknown
E. coli/Shigella spp.
E. faecalis E. faecalis
F. nucleatum
S. anginosus
Staphylococcus
epidermidis
S. epidermidis
16 Abscess subcut.§ E. faecium E. faecium E. faecium CI, OX
Finegoldia magna F. magna F. magna
17 Abscess retro-
peritoneal§
E. faecium E. faecium/hirae E. faecium/hirae CI, MZ, LZ
Klebsiella pneumoniae K. pneumoniae
18 Bile§ E. coli E. coli/Shigella spp. E. coli/Shigella spp. CT, MZ
F. nucleatum F. nucleatum
19 Bile E. caccae IP
Enterococcus sp. E. casseliflavus/gallinarum E. casseliflavus/gallinarum
E. faecalis
CNS S. epidermidis S. epidermidis
20 Empyema No growth P. micrad P. micra PT
Prevotella nigrescens
Peptostreptococcus stomatis P. stomatis
S. anginosus S. anginosus
21 Empyema§ C. gracilis C. gracilis CT, GE, PC
Fusobacterium sp. Fusobacterium sp.
S. intermedius S. intermedius S. intermedius
22 Empyema F. nucleatum F. nucleatum CT, PC
C. gracilis
P. micra P. micra
S. intermedius S. intermedius S. intermedius
23 Empyema C. gracilis CI, CL
F. nucleatum
Haemophilus parainfluenzae
P. melaninogenicad P. melaninogenica
P. micra
S. constellatus S. constellatus
diphtheroid
CNS
24 Empyema C. gracilis C. gracilis PC
E. corrodens E. corrodens
P. micra
Prevotella pleuritidis P. pleuritidis
S. intermedius
S. parasanguinis
25 Empyema Prevotella sp. P. nigrescens P. nigrescens CT
Prevotella veroralis P. veroralis
Direct 16S rDNA sequencing with group-specific primers
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Acinetobacter spp., Comamonas spp., Pseudomonas spp. and
Sphingomonas spp.) and the PCR was judged to be a false
positive. The remaining 98 PCRs were negative as expected.
DISCUSSION
Detection and identification of bacteria directly from
polymicrobial clinical samples by broad-range PCR
followed by DNA sequencing can be accomplished using
RipSeq mixed chromatogram analysis. In this study we
replaced the standard universal 16S rRNA gene PCR with a
set of three separate group-specific PCRs, reducing the risk
of species present at lower concentrations becoming
outcompeted in the amplification step. The importance
of this factor is illustrated by the fact that only eight of the
chromatograms obtained with the universal primers were
judged to contain more than three bacterial sequences
(Table 2).
The group-specific PCRs significantly increased the
number of identified bacteria as compared to amplification
with a universal PCR (95 versus 51, P,0.05 by Wilcoxon
signed-rank test; Altman, 1991). All bacteria identified by
standard universal direct sequencing and RipSeq analysis
were also found with the group-specific primers and
RipSeq analysis. Since the species combinations in the
chromatograms obtained with the universal versus the
group-specific primers for the most part were different, this
is a confirmation of RipSeq’s ability to analyse mixed DNA
chromatograms. In addition 18 of the bacteria identified as
part of a mixed chromatogram with the universal primer
pair were recovered as non-mixed chromatograms with
one of the group-specific primer pairs.
Discrimination between the three groups of bacteria was
based on the forward primers alone, and the difference
between forward primers A and C was a single nucleotide
at the 39-terminal position only (Table 1). In order to
obtain sufficient primer discrimination we used locked
nucleic acids (LNAs). LNAs increase the impact of a
mismatch in the actual and the subsequent base position.
When placed in the penultimate 39-end position an LNA
protects the 39-end terminal base from the proofreading
39–59-exonuclease activity of the TaKaRa polymerase. In
combination with this primer design, polymerases without
39–59-exonuclease activity have been reported to provide
less robust discrimination (Di Giusto & King, 2004; Rupp
et al., 2006). LNAs were also useful for harmonizing primer
annealing temperatures.
In a set of group-specific primers the number of primer
pairs will be a compromise between the possibilities given
by the chosen gene target, sensitivity and practical
considerations. For maximum effect, relevant bacterial
species should distribute evenly between the primer pairs
and cross-reactivity should be low. We found an almost
perfect distribution for the species included in the pre-
study alignments, and we also saw a good distribution in
the study: 42 species were targeted by primer pair A, 20 by
primer pair B and 33 by primer pair C. Given that two
targets belong to different primer groups the primers
described here will accommodate ratios of 1:1000 or
higher. With two targets from the same group the situation
will be equivalent to what we see with a single universal
primer pair, where successful detection of both targets
cannot be expected with ratios higher than 1:10.
A negative control containing a mixed DNA population in
low concentration could give low reproducibility with the
group-specific primers due to random distribution of the
different DNA targets in the respective reaction tubes. We
also considered that low-level DNA contamination in a
specimen could have a different composition from low-
level DNA contamination in the negative control (due to
e.g. sample collection and transportation tubes). Conse-
quently, in reactions where the negative control did not
contain any target DNA a poor amplification would lead to
a very high Ct value that subsequently could define a
negative sample as positive. For these reasons, although the
negative control was included in all group-specific PCRs,
the PCR in which it became positive first defined the cut-
off for a positive sample for all three reactions. With the
definition of a positive PCR used in this study, we got two
false-positive PCRs. Although none of the false positive
PCRs resulted in findings that would have been reported,
we suggest including a second criterion stating that in
order to be defined as positive, a sample has to reach Ct
Table 2. cont.
ID Sample type Culture* Universal primer Group-specific primers AntibioticD
Anaerobic Gram+ve rod Dialister invisus
Dialister micraerophilus
P. micra
*CNS, coagulase negative Staphylococcus.
DAntibiotics: –, no treatment; AM, amoxicillin; CI, ciprofloxacin; CL, clindamycin; CT, cefotaxime; CX, ceftriaxone; GE, gentamicin; IP, imipenem;
LZ, linezolid; MP, meropenem; MZ, metronidazole; OX, oxacillin; PC, penicillin-G; PT, piperacillin-tazobactam; RI, rifampicin; VA, vancomycin.
dChromatogram too complex to allow for complete analysis. Only dominant peaks included.
§Samples with identical results for standard direct sequencing and group-specific direct sequencing.
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Species in parenthesis (n55) indicates cross-reactivity between primer groups.
ID Sample type Primer pair A Primer pair B Primer pair C
1 Abscess brain Gemella haemolysans/morbillorum – Fusobacterium nucleatum
Parvimonas sp.
Streptococcus intermedius*
2 Abscess brain S. intermedius – F. nucleatum
3 Abscess brain Parvimonas micra Aggregatibacter aphrophilusD F. nucleatum
S. intermedius Eikenella corrodens F. nucleatum subsp.
polymorphum Neisseria elongata
4 Abscess brain Actinomyces meyeri Campylobacter gracilis F. nucleatum
S. intermedius Prevotella pleuritidis
5 Abscess brain A. meyeri C. gracilis Fusobacterium sp.
Peptostreptococcus sp. Eikenella sp.
6 Abscess liver Enterococcus faecium/durans Escherichia coli/Shigella spp.D Lactobacillus rhamnosus
Staphylococcus haemolyticus
7 Abscess liver G. haemolysans – Prevotella melaninogenica
Streptococcus mitis group (S. parasanguinis)
Streptococcus parasanguinis
8 Abscess liver – E. coli/Shigella spp. Clostridium perfringens
9 Abscess muscle P. micra E. corrodens F. nucleatum
S. constellatus/intermedius Porphyromonas circumdentaria
10 Abscess ovarian Parvimonas sp. – F. nucleatum
11 Abscess pancreas Enterococcus faecium
(Bacteroides fragilis)
– Bacteroides fragilis
12 Abscess pancreas A. meyeri (P. melaninogenica) Campylobacter concisus P. melaninogenica/histicola
Staphylococcus epidermidis
13 Abscess para-aortic Corynebacterium
tuberculostearicum
– S. haemolyticus/epidermidis
Corynebacterium appendicis
14 Abscess psoas E. faecium Enterobacter hormaechei –
15 Abscess spleen Enterococcus casseliflavus/gallinarum E. coli/Shigella spp. F. nucleatum
Enterococcus faecalis S. epidermidis
Streptococcus anginosus
16 Abscess subcutaneous E. faecium – (E. faecium)
Finegoldia magna (F. magna)
17 Abscess retroperitoneal E. faecium/durans Klebsiella pneumoniae –
18 Bile – E. coli/Shigella spp. F. nucleatum
19 Bile Enterococcus caccae – S. epidermidis
E. casseliflavus/gallinarum
E. faecalis
20 Empyema P. micra – Prevotella nigrescens
S. anginosus Peptostreptococcus stomatis
21 Empyema S. intermedius C. gracilis Fusobacterium sp.
22 Empyema P. micra C. gracilis F. nucleatum
S. intermedius
23 Empyema P. micra C. gracilis F. nucleatum
S. constellatus Haemophilus parainfluenzae P. melaninogenica
24 Empyema P. micra C. gracilis Prevotella pleuritidis
Direct 16S rDNA sequencing with group-specific primers
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cycles before the negative control. In our experience
reactions with higher Ct values are of doubtful significance
and rarely result in relevant findings. This additional rule
would not have affected the results in Tables 2 and 3.
By using group-specific primers the cost per analysis will
see some increase. We kept the increase in both price and
workload as low as possible by sequencing in one direction
only, and the average number of sequencing reactions in
our material was 2.55 per positive sample. There are seve-
ral publications based on mono-directional sequencing,
and it is also used in a commercially available 16S rDNA
sequencing kit (Bosshard et al., 2003, 2004; Wellinghausen
et al., 2009). With the high fidelity of today’s PCR and
Sanger sequencing reactions the main reason for bidirec-
tional sequencing is to obtain maximum read lengths and
better discrimination between similar species. If we ignore
the primer-binding areas which are of no value for
identification, a reduction of 40–50 readable bases can be
Table 4. Results obtained for the presumably sterile samples by culture and by the two direct sequencing protocols
ID Specimen Culture Universal PCR Group-specific PCRs Antibiotics*
ABC
26 Abscess liver (amoebic) No growth Neg Neg Neg Neg Unknown
27 Abscess lung (aspergilloma) No growth Neg Neg Neg Neg CT
28 Abscess neck (tumor colli) No growth Neg Neg Neg Neg –
29 Abscess pelvic (cancer) No growth Neg Neg Neg Neg Unknown
30 Abscess subcutaneous (cancer) No growth Neg Neg Neg Neg CF
31 Biopsy bone No growth Neg Neg Neg Neg –
32 Pericardial fluid No growth Neg Neg Neg Neg GE, PC
33 Pericardial fluid No growth Neg Neg Neg Neg AM, CI
34 Pericardial fluid No growth Neg Neg Neg Neg Unknown
35 Peritoneal fluid No growth PosD Neg Neg Neg OX
36 Peritoneal fluid No growth Neg Neg Neg Neg –
37 Pleural fluid No growth Neg Neg Neg Neg –
38 Pleural fluid No growth Neg Neg Neg Neg –
39 Pleural fluid No growth Neg Neg Neg Neg –
40 Pleural fluid No growth Neg Neg Neg Neg –
41 Pleural fluid No growth Neg Neg Neg Neg –
42 Pleural fluid No growth Neg Neg Neg Neg Unknown
43 Subdural haematoma No growth Neg Neg Neg Neg –
44 Synovial fluid No growth Neg Neg Neg Neg Unknown
45 Synovial fluid No growth Neg Neg Neg Neg –
46 Synovial fluid No growth Neg Neg Neg Neg Unknown
47 Synovial fluid No growth Neg Neg Neg Neg –
48 Tissue prosthetic joint No growth Neg Neg Neg Neg Unknown
49 Tissue prosthetic joint No growth Neg Neg Neg Neg –
50 Tissue prosthetic joint No growth Neg Neg Posd Neg –
*Antibiotics: AM, amoxicillin; CI, ciprofloxacin; CF, cefalotin; CT, cefotaxime; GE, gentamicin; OX, oxacillin; PC, penicillin.
DDistance to negative control 3.0 cycles; Ct531.5.
dDistance to closest negative control 3.1 cycles; Ct530.6.
Table 3. cont.
ID Sample type Primer pair A Primer pair B Primer pair C
S. intermedius E. corrodens
25 Empyema Dialister invisus – P. nigrescens D
Dialister micraerophilus Prevotella veroralis
P. micra
*Differentiation between S. constellatus and S. intermedius based on type strains only.
DChromatogram too complex to allow for complete analysis. Only dominant peaks included.
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encing. With our primers this led to a 40–50% reduction
in the number of readable bases in the variable area V3,
whereas the variable areas V1 and V2 remained intact
(Baker et al., 2003). We find the potential reduction in
resolution to the species level defendable when compared
to the significant increase in identifiable bacteria. The
only visible consequence of mono-directional sequen-
cing in this study was found in sample 12, where the
better discrimination between Prevotella histicola and P.
melaninogenica in the forward direction allowed for an
‘and’ instead of an ‘and/or’ identification with the universal
protocol. A rational approach will be to use a single
universal primer pair for specimens expected to be
monobacterial (e.g. cerebrospinal fluid and synovial fluid)
and reserve the group-specific primers for specimens
known to frequently contain multiple organisms (e.g.
abscesses, pleural fluid and bile).
It is clear from this and other studies that the results
achieved by routine culture-based diagnostics alone are not
sufficient when it comes to patients who have received one
or more doses of antibiotics prior to sample collection, or
the investigation of anaerobe infections (Al Masalma et al.,
2009; Goldenberger et al., 1997; Kommedal et al., 2009;
Petti et al., 2008b; Schuurman et al., 2004; Senn et al.,
2005). Infectious-disease physicians are well aware of these
limitations. As a consequence microbiological results are
currently not so often used to tailor individual antibiotic
treatment, but more to look for the unexpected organisms
that eventually should lead to a diversion from standard
empirical therapy. Compared to culture, sequencing with
group-specific primers detected on average 2.5 times as
many species per sample including important pathogens
such as Actinomyces meyeri, Campylobacter gracilis (de
Vries et al., 2008; Johnson et al., 1985), Escherichia coli,
Fusobacterium nucleatum and HACEK group bacteria
(Haemophilus parainfluenzae, Aggregatibacter aphrophilus
and Eikenella corrodens). Failure to detect these organisms
can lead to inadequate antimicrobial coverage, in particular
in situations where first-line empirical treatment cannot be
used or when patients are to be transferred to oral
treatment. For the brain abscesses our findings correlate
well with what was described in a study by Al Masalma et
al. (2009) using cloning and second-generation sequencing.
Although these methods can provide even higher resolu-
tion in some situations, today they remain research tools
due to long investigation time and high costs.
For the uncultured organisms there will be no antimicro-
bial susceptibility results to guide treatment. Since some of
these species may be unfamiliar to the clinical doctors,
adding comments on the general susceptibility patterns for
these species to the lab reports may contribute to assuring
adequate patient treatment and also to preventing
unnecessary use of broad-spectrum antibiotics. Many of
the species detected exclusively by sequencing in this study
(e.g. the anaerobic bacteria) have relatively unproblematic
susceptibility patterns.
The purposes of this study were to demonstrate the
potential of the group-specific PCRs and to establish a
robust protocol. The approach can contribute to better
characterization of polybacterial clinical samples and has
the advantage that it can be readily implemented in any
diagnostic laboratory with experience in standard direct
sequencing.
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